3,4‐Diaminopyridine vs placebo
Adverse events · participants with Lambert‐Eaton myasthenic syndrome
1 finding from 1 review
- no estimate extracted4 studies · 42 participantsHigh
Findings
What do systematic reviews say?
13 questions · 13 findings · 7 reviews · Neuromuscular
No studies found 2 · 15.4%GRADE not reported 0 · 0%Very low 2 · 15.4%Low 4 · 30.8%Moderate 3 · 23.1%High 2 · 15.4%
Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily)
Adverse events · patients with established cardiomyopathy in DMD
1 finding from 1 review
- Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Inotersen vs placebo
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes onlyRR 8.57 [1.16, 63.07]1 study · 172 participantsLow
Intervention not reported
Minor adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in minor adverse events (low certainty).
1 finding from 1 review
- RR 1.51 [0.98, 2.33]4 studies · 254 participantsLow
Quinine vs a quinine‐vitamin E combination (Q‐Vel)
Minor adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted3 studies · 510 participantsModerate
Quinine vs placebo
Minor adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted16 studies · 969 participantsModerate
Quinine vs vitamin E
Minor adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted2 studies · 483 participantsModerate
Intervention not reported
Adverse events · participants with resistant CTEV
1 finding from 1 review
- no estimate extracted1 study · 4 participantsVery low
Intervention not reported
Adverse events · participants with relapsed or recurrent CTEV
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Adverse events · participants with neglected CTEV
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Adverse events · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified)
1 finding from 1 review
- no estimate extracted1 study · 5 participantsLow
Intervention not reported
Adverse events · participants with CTEV at initial presentation
The intervention may leads to lower adverse events (low certainty).
1 finding from 1 review
- no estimate extracted1 study · 25 participantsLow
Intervention not reported
Adverse events · people with ALS/MND
1 finding from 1 review
- Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 353 participantsHigh